Download PDF
Clin Colon Rectal Surg 2006; 19(2): 069-077
DOI: 10.1055/s-2006-942347
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Colorectal Gastrointestinal Stromal Tumors: A Brief Review

Rishindra M. Reddy1 , James W. Fleshman2
  • 1Department of Surgery, Washington University School of Medicine, St. Louis, Missouri
  • 2Section of Colon and Rectal Surgery; Washington University School of Medicine, St. Louis, Missouri
Further Information

Publication History

Publication Date:
23 May 2006 (online)

    Permissions and Reprints

ABSTRACT

Gastrointestinal stromal tumors (GISTs) are rare lesions that constitute the majority of mesenchymal tumors in the gastrointestinal tract. Within the colon and rectum, they represent 0.1% of all cancers. They can present with a variety of symptoms but are often asymptomatic. Although many lesions may be benign, up to half of patients develop recurrent disease within a few years. Almost all GISTs contain a mutation in the c-kit tyrosine kinase that leads to its constitutive activation and results in cell proliferation. This discovery has led to the immunostaining of the c-kit antigen (CD117) to distinguish GISTs from other malignancies. Radiologic examinations can be helpful in initial diagnosis and staging. Surgery is the best treatment for cure, but recent advances have led to the use of imatinib mesylate, a tyrosine kinase inhibitor, to treat metastatic or unresectable disease, or both. There are currently many clinical trials available to help treat GISTs.

KEYWORDS

Gastrointestinal stromal tumors - colon cancer - imatinib mesylate - CD117/c-kit - surgery

REFERENCES

  • 1 Pidhorecky I, Cheney R T, Kraybill W F, Gibbs J F. Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management.  Ann Surg Oncol. 2000;  7 705-712
    CrossrefPubMedGoogle Scholar
  • 2 Miettinen M, Majidi M, Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review.  Eur J Cancer. 2002;  38(suppl 5) S39-S51
    Google Scholar
  • 3 Stout A P. Bizarre smooth muscle tumors of the stomach.  Cancer. 1962;  15 400-409
    PubMedGoogle Scholar
  • 4 Appelman H D. Smooth muscle tumors of the gastrointestinal tract. What we know now that Stout didn't know.  Am J Surg Pathol. 1986;  10(suppl 1) 83-99
    PubMedGoogle Scholar
  • 5 Mazur M T, Clark H B. Gastric stromal tumors: reappraisal of histogenesis.  Am J Surg Pathol. 1983;  7 507-519
    CrossrefPubMedGoogle Scholar
  • 6 Miettinen M, Sarlomo-Rikala M, Lasota J. Gastrointestinal stromal tumors: recent advances in understanding of their biology.  Hum Pathol. 1999;  30 1213-1220
    CrossrefPubMedGoogle Scholar
  • 7 Nilsson B, Bumming P, Meis-Kindblom J M et al.. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era.  Cancer. 2005;  103 821-829
    CrossrefPubMedGoogle Scholar
  • 8 Robinson T L, Sircar K, Hewlett B R, Chorneyko K, Riddel R H, Huizinga J D. Gastrointestinal stromal tumors may originate from a subset of CD34-positive interstitial cells of Cajal.  Am J Pathol. 2000;  156 1157-1163
    CrossrefPubMedGoogle Scholar
  • 9 Sircar K, Hewlett B R, Huizinga J D, Chorneyko K, Berezin I, Riddell R H. Interstitial cells of Cajal as precursors for gastrointestinal stromal tumors.  Am J Surg Pathol. 1999;  23 377-389
    CrossrefPubMedGoogle Scholar
  • 10 Kindblom L G, Remotti H E, Aldenborg F, Meis-Kindblom J M. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.  Am J Pathol. 1998;  152 1259-1269
    PubMedGoogle Scholar
  • 11 Berman J, O'Leary T J. Gastrointestinal Stromal Tumor Workshop.  Hum Pathol. 2001;  32 578-582
    CrossrefPubMedGoogle Scholar
  • 12 Miettinen M, Furlong M, Sarlomo-Rikala M, Burke A, Sobin L H, Lasota J. Gastrointestinal stromal tumors, intramural leiomyomas, and leiomyosarcomas in the rectum and anus: a clinicopathologic, immunohistochemical, and molecular genetic study of 144 cases.  Am J Surg Pathol. 2001;  25 1121-1133
    CrossrefPubMedGoogle Scholar
  • 13 Hirota S, Isozaki K, Moriyama Y et al.. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.  Science. 1998;  279 577-580
    CrossrefPubMedGoogle Scholar
  • 14 http://www.glivec.com/images/
  • 15 Tuveson D A, Willis N A, Jacks T et al.. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications.  Oncogene. 2001;  20 5054-5058
    CrossrefPubMedGoogle Scholar
  • 16 Hirota S, Nishida T, Isozaki K et al.. Gain-of-function mutation at the extracellular domain of KIT in gastrointestinal stromal tumours.  J Pathol. 2001;  193 505-510
    PubMedGoogle Scholar
  • 17 van der Zwan S M, DeMatteo R P. Gastrointestinal stromal tumor: 5 years later.  Cancer. 2005;  104 1781-1788
    CrossrefPubMedGoogle Scholar
  • 18 Tran T, Davila J A, El-Serag H B. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000.  Am J Gastroenterol. 2005;  100 162-168
    CrossrefPubMedGoogle Scholar
  • 19 Hasegawa T, Matsuno Y, Shimoda T, Hirohashi S. Gastrointestinal stromal tumors: consistent CD117 immunostaining for diagnosis, and prognostic classification based on tumor size and MIB-1 grade.  Hum Pathol. 2002;  33 669-676
    CrossrefPubMedGoogle Scholar
  • 20 Miettinen M, Sarlomo-Rikala M, Sobin L H, Lasota J. Gastrointestinal stromal tumors and leiomyosarcomas in the colon: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases.  Am J Surg Pathol. 2000;  24 1339-1352
    CrossrefPubMedGoogle Scholar
  • 21 Conlon K C, Casper E S, Brennan M F. Primary gastrointestinal sarcomas: analysis of prognostic variables.  Ann Surg Oncol. 1995;  2 26-31
    CrossrefPubMedGoogle Scholar
  • 22 DeMatteo R P, Lewis J J, Leung D, Mudan S S, Woodruff J M, Brennan M F. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.  Ann Surg. 2000;  231 51-58
    CrossrefPubMedGoogle Scholar
  • 23 Burkill G JC, Badran M, Al-Muderis O et al.. Malignant gastrointestinal stromal tumor: distribution, imaging features, and pattern of metastatic spread.  Radiology. 2003;  226 527-532
    Google Scholar
  • 24 Orosz Z, Tornoczky T, Sapi Z. Gastrointestinal stromal tumors: a clinicopathologic and immunohistochemical study of 136 cases.  Pathol Oncol Res. 2005;  11 11-21
    PubMedGoogle Scholar
  • 25 Greenson J K. Gastrointestinal stromal tumors and other mesenchymal lesions of the gut.  Mod Pathol. 2003;  16 366-375
    CrossrefPubMedGoogle Scholar
  • 26 Horton K M, Juluru K, Montogomery E, Fishman E K. Computed tomography imaging of gastrointestinal stromal tumors with pathology correlation.  J Comput Assist Tomogr. 2004;  28 811-817
    PubMedGoogle Scholar
  • 27 Emory T S, Sobin L H, Lukes L, Lee D H, O'Leary T J. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site.  Am J Surg Pathol. 1999;  23 82-87
    CrossrefPubMedGoogle Scholar
  • 28 Tateishi U, Hasegawa T, Satake M, Moriyama N. Gastrointestinal stromal tumor; correlation of computed tomography findings with tumor grade and mortality.  J Comput Assist Tomogr. 2003;  27 792-798
    CrossrefPubMedGoogle Scholar
  • 29 Kurokawa Y, Nishisho I, Kawahara K, Mishima H, Hirota S, Kikkawa N. Gastrointestinal stromal tumor of the rectum with activating mutation of c-kit: report of a case.  Dis Colon Rectum. 2000;  43 1316-1318
    CrossrefPubMedGoogle Scholar
  • 30 Shibata Y, Ueda T, Seki H, Yagihashi N. Gastrointestinal stromal tumour of the rectum.  Eur J Gastroenterol Hepatol. 2001;  13 283-286
    CrossrefPubMedGoogle Scholar
  • 31 Michalopoulos A, Papadopoulos V N, Basdanis G et al.. Colorectal gastrointestinal mesenchymal tumours. Report of a stromal case of the rectum (GIST) and leiomyosarcoma of the transverse colon.  Tech Coloproctol. 2004;  8(suppl 1) s155-s157
    CrossrefPubMedGoogle Scholar
  • 32 Lo S S, Papachristou G I, Finkelstein S D, Conroy W P, Schraut W H, Ramanathan R K. Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: report of a case.  Dis Colon Rectum. 2005;  48 1316-1319
    CrossrefPubMedGoogle Scholar
  • 33 Gupta S, Punia R S, Kaushik R. Gastrointestinal stromal tumour of the colon presenting with intestinal obstruction.  Indian J Cancer. 2004;  41 175-177
    PubMedGoogle Scholar
  • 34 Neuhaus S J, Clark M A, Hayes A J, Thomas J M, Judson I. Surgery for gastrointestinal tumour in the post-imatinib era.  ANZ J Surg. 2005;  75 165-172
    CrossrefPubMedGoogle Scholar
  • 35 Levy A D, Remotti H E, Thompson W M, Sobin L H, Miettinen M. Anorectal gastrointestinal stromal tumors: CT and MR imaging features with clinical and pathologic correlation.  AJR Am J Roentgenol. 2003;  180 1607-1612
    PubMedGoogle Scholar
  • 36 Tworek J A, Goldblum J R, Weiss S W, Greenson J K, Appelman H D. Stromal tumors of the anorectum: a clinicopathologic study of 22 cases.  Am J Surg Pathol. 1999;  23 946-954
    CrossrefPubMedGoogle Scholar
  • 37 McGrath P C, Neifeld J P, Lawrence Jr W, Kay S, Horsley III J S, Parker G A. Gastrointestinal sarcomas. Analysis of prognostic factors.  Ann Surg. 1987;  206 706-710
    PubMedGoogle Scholar
  • 38 Hama Y, Okizuka H, Odajima K, Hayakawa M, Kusano S. Gastrointestinal stromal tumor of the rectum.  Eur Radiol. 2001;  11 216-219
    CrossrefPubMedGoogle Scholar
  • 39 Van den Berg J C, van Heesewijk J P, van Es H W. Malignant stromal tumour of the rectum: findings at endorectal ultrasound and MRI.  Br J Radiol. 2000;  73 1010-1012
    PubMedGoogle Scholar
  • 40 Hsieh J S, Huang C J, Wang J Y, Huang T J. Benefits of endorectal ultrasound for management of smooth-muscle tumor of the rectum: report of three cases.  Dis Colon Rectum. 1999;  42 1085-1088
    PubMedGoogle Scholar
  • 41 Connolly E M, Gaffney E, Reynolds J V. Gastrointestinal stromal tumours.  Br J Surg. 2003;  90 1178-1186
    CrossrefPubMedGoogle Scholar
  • 42 Fletcher C D, Berman J J, Corless C et al.. Diagnosis of gastrointestinal stromal tumors: a consensus approach.  Hum Pathol. 2002;  33 459-465
    Google Scholar
  • 43 Tworek J, Goldblum J R, Weiss S W, Greenson J K, Appelman H D. Stromal tumors of the abdominal colon: a clinicopathologic study of 20 cases.  Am J Surg Pathol. 1999;  23 937-945
    CrossrefPubMedGoogle Scholar
  • 44 Miettinen M, Sobin L H, Sarlomo-Rikala M. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT).  Mod Pathol. 2000;  13 1134-1142
    CrossrefPubMedGoogle Scholar
  • 45 Miettinen M, Lasota J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics.  Pol J Pathol. 2003;  54 3-24
    PubMedGoogle Scholar
  • 46 Sarlomo-Rikala M, Kovatich A J, Barusevicius A, Miettinen M. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34.  Mod Pathol. 1998;  11 728-734
    PubMedGoogle Scholar
  • 47 Yamaguchi U, Hasegawa T, Masuda T et al.. Differential diagnosis of gastrointestinal stromal tumor and other spindle cell tumors in the gastrointestinal tract based on immunohistochemical analysis.  Virchows Arch. 2004;  445 142-150
    PubMedGoogle Scholar
  • 48 Daum O, Hes O, Vanecek T et al.. Vanek's tumor(inflammatory fibroid polyp). Report of 18 cases and comparison with three cases of original Vanek's series.  Ann Diagn Pathol. 2003;  7 337-347
    PubMedGoogle Scholar
  • 49 Miettinen M, Sarlomo-Rikala M, Sobin L H. Mesenchymal tumors of muscularis mucosae of colon and rectum are benign leiomyomas that should be separated from gastrointestinal stromal tumors-a clinicopathologic and immunohistochemical study of eighty-eight cases.  Mod Pathol. 2001;  14 950-956
    CrossrefPubMedGoogle Scholar
  • 50 Dougherty M J, Compton C, Talbert M, Wood W C. Sarcomas of the gastrointestinal tract. Separation into favorable and unfavorable prognostic groups by mitotic count.  Ann Surg. 1991;  214 569-574
    CrossrefPubMedGoogle Scholar
  • 51 Lee C H, Jan Y J, Chen J T, Ho W L, Tseng C H, Wang J. Colorectal mesenchymal tumor: a clinicopathologic study of 25 cases.  J Chin Med Assoc. 2005;  68 291-298
    PubMedGoogle Scholar
  • 52 Haque S, Dean P J. Stromal neoplasms of the rectum and anal canal.  Hum Pathol. 1992;  23 762-767
    CrossrefPubMedGoogle Scholar
  • 53 Chak A, Canto M I, Rosch T et al.. Endosonographic differentiation of benign and malignant stromal cell tumors.  Gastrointest Endosc. 1997;  45 468-473
    CrossrefPubMedGoogle Scholar
  • 54 Taniguchi M, Nishida T, Hirota S et al.. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.  Cancer Res. 1999;  59 4297-4300
    PubMedGoogle Scholar
  • 55 Sturgeon C, Chejfec G, Espat N J. Gastrointestinal stromal tumors: a spectrum of disease.  Surg Oncol. 2003;  12 21-26
    CrossrefPubMedGoogle Scholar
  • 56 Plaat B E, Hollema H, Molenaar W M et al.. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins.  J Clin Oncol. 2000;  18 3211-3220
    PubMedGoogle Scholar
  • 57 Masuoka H, Kawagishi N, Inoue T et al.. Giant hepatic metastasis from gastrointestinal stromal tumor of the rectum 12 years after surgery.  Hepatogastroenterology. 2003;  50 1454-1456
    PubMedGoogle Scholar
  • 58 Lanteri R, Aliotta I, Racalbuto A, Licata A. Anal GIST in older old patient: a case report.  G Chir. 2005;  26 135-137
    PubMedGoogle Scholar
  • 59 Van Oosterom A T, Judson I, Verweij J et al.. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study.  Lancet. 2001;  358 1421-1423
    CrossrefPubMedGoogle Scholar
  • 60 Demetri G D, von Mehren M, Blanke C D et al.. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.  N Engl J Med. 2002;  347 472-480
    CrossrefPubMedGoogle Scholar
  • 61 Van Glabbeke M, Verweij J, Casali P G et al.. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.  J Clin Oncol. 2005;  23 5795-5804
    CrossrefPubMedGoogle Scholar
  • 62 Dagher R, Cohen M, Williams G et al.. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors.  Clin Cancer Res. 2002;  8 3034-3038
    PubMedGoogle Scholar
  • 63 Vanel D, Albiter M, Shapeero L et al.. Role of computed tomography in the follow-up of hepatic and peritoneal metastases of GIST under imatinib mesylate treatment: a prospective study of 54 patients.  Eur J Radiol. 2005;  54 118-123
    CrossrefPubMedGoogle Scholar
  • 64 Joensuu H, Roberts P J, Sarlomo-Rikala M et al.. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.  N Engl J Med. 2001;  344 1052-1056
    CrossrefPubMedGoogle Scholar
  • 65 Antoch G, Kanja J, Bauer S et al.. Comparison of PE, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors.  J Nucl Med. 2004;  45 357-365
    PubMedGoogle Scholar
  • 66 Scaife C L, Hunt K K, Patel S R et al.. Is there a role for surgery in patients with “unresectable” cKIT + gastrointestinal stromal tumors treated with imatinib mesylate?.  Am J Surg. 2003;  186 665-669
    CrossrefPubMedGoogle Scholar
  • 67 Koon N, Schneider-Stock R, Sarlomo-Rikala M et al.. Molecular targets for tumour progression in gastrointestinal stromal tumours.  Gut. 2004;  53 235-240
    CrossrefPubMedGoogle Scholar
  • 68 http://www.cancer.gov/clinicaltrials/

Rishindra M ReddyM.D. 

Department of Surgery, Washington University School of Medicine, House Staff Office

Campus Box 8109, 1701 West Bldg., 660 S. Euclid Ave., St. Louis, MO 63110

Email: reddyr@wudosis.wustl.edu

      >